Poster
I-DXd
ISPOR 2026 | May 17-20, 2026
Lung Cancer
An indirect treatment comparison of ifinatamab deruxtecan (I-DXd) versus real-world physicians’ choice of therapy in patients previously treated with at least 2 lines of therapy for extensive-stage small cell lung cancer
Jie Meng
Poster
Dato-DXd
ISPOR 2026 | May 17-20, 2026
Breast Cancer
Estimating meaningful change thresholds (MCTs) for European Organisation for Research and Treatment of Cancer (EORTC) scales in a phase 3 trial for patients with locally recurrent inoperable or metastatic triple-negative breast cancer
Nikki Ow
Poster
T-DXd
ISPOR 2026 | May 17-20, 2026
Other/Multi
Patient preferences for treatment benefits in metastatic solid cancers: A systematic literature review
Alexandra Jager
Poster
R-DXd
ISPOR 2026 | May 17-20, 2026
Gynecologic Cancers
Real-world treatment patterns and outcomes in US platinum-resistant ovarian cancer patients: Characterizing the unmet clinical need
Kathleen N. Moore
Poster
I-DXd
ISPOR 2026 | May 17-20, 2026
Lung Cancer
Real-world treatment patterns, outcomes, HCRU, and costs associated with previously treated extensive-stage SCLC in the US following the approval of newer treatment options
Melissa L. Santorelli